- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07504848
Stroke Mobility and Caregiver Outcomes
Effekten av rörlighetsnivå hos stroke-patienter på ångest, depression och omsorgsgivarbörda hos omsorgsgivare
This study was designed to determine the effect of functional mobility levels of stroke patients on caregiver burden, anxiety, and depression in their caregivers.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Atakum
-
Samsun, Atakum, Turkiet (Türkiye), 55270
- Ondokuz Mayis University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
This study includes adult individuals with a first-ever unilateral stroke and their primary caregivers. Stroke patients aged 18-75 years, at least 3 months post-stroke, with sufficient cognitive function (MMSE ≥24), and stable medical status are included. Caregivers are adults who have been living with the patient for at least one year and are the primary, non-professional caregivers.
Beskrivning
Inclusion Criteria:
-
Stroke Patients:
- Diagnosed with stroke according to WHO criteria (≥20% disability rate documented in Adult Disability Health Board Report)
- Having a family member or relative who provides care
- First-ever and unilateral stroke
- Willing to participate voluntarily
- Aged between 18-75 years
- Post-stroke duration longer than 3 months
- Stable vital signs
- Scoring ≥24 on the Standardized Mini-Mental State Examination (SMMT) or the -Modified Mini-Mental State Examination for Illiterate Individuals (MMSE-E)
- Able to understand and speak Turkish
-
Caregivers of Stroke Patients:
- Willing to participate in the study
- Living with the patient for at least 1 year
- Being the primary (main responsible) caregiver and not receiving paid professional caregiving services
- Aged 18 years or older
- Scoring ≥24 on the Standardized Mini-Mental State Examination (SMMT) or MMSE-E
Exclusion Criteria:
-
Stroke Patients:
- Presence of severe comorbid conditions
- Unwillingness to participate
- History of multiple strokes
- Bilateral hemiplegia
- Presence of major neurological, orthopedic, or rheumatologic disorders affecting the musculoskeletal system other than stroke
- Congenital anomalies or amputation causing disability
- Uncontrolled arrhythmia, uncontrolled hypertension, or unstable cardiac conditions
- Botulinum toxin injection within the last 6 months
- Inability to establish cooperation
- Presence of neglect, aphasia, or hemianopsia
-
Caregivers of Stroke Patients:
- Unwillingness to participate
- Living with the patient for less than 1 year
- Presence of mental retardation, dementia, or severe psychotic disorders
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: OTHER
- Tidsperspektiv: CROSS_SECTIONAL
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Vårdgivare
|
|
Strokepatienter
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Brunnstroms stadier av hemiplegisk återhämtning
Tidsram: Baslinje
|
Baslinje
|
|
|
Burden Interview
Tidsram: Baslinje
|
Baslinje
|
|
|
Tidsuppmätt upp-och-gå-test
Tidsram: Baslinje
|
Baslinje
|
|
|
Beck Depression Inventory
Tidsram: Baseline
|
The Beck Depression Inventory (BDI) is scored between 0 and 63, where 0 indicates minimal or no depressive symptoms and 63 reflects severe depression; increasing scores correspond to greater severity of depressive symptomatology. |
Baseline
|
|
Beck Anxiety Inventory
Tidsram: Baseline
|
Beck Anxiety Inventory (BAI) ranges from 0 to 63, with 0 indicating minimal anxiety and 63 indicating severe anxiety; higher scores represent increased severity of anxiety symptoms. |
Baseline
|
|
Rivermead Mobility Index
Tidsram: Baseline
|
The Rivermead Mobility Index (RMI) ranges from 0 to 15. 0 indicates severe dependence with inability to perform basic mobility tasks. 15 indicates full independence in all assessed mobility activities. As the score increases, it reflects a progressive improvement in functional mobility, with greater independence in activities such as transfers, walking, and balance. |
Baseline
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2025/105
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .